Skip to content
MedsAcross

Medicine

Sulfatrim 200 mg/40 mg per 5 mL oral suspension

Sulfamethoxazole and Trimethoprim · Oral · PAI Pharma
Available on requestPrescription onlyUS FDA

Sulfatrim 200 mg/40 mg per 5 mL oral suspension is a prescription medicine containing Sulfamethoxazole and Trimethoprim for oral use, marketed by PAI Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20°-25°C (68°-77°F). Protect from light.

Key facts

Active ingredient (INN)
Sulfamethoxazole and Trimethoprim
Brand
Sulfatrim
Strength
200 mg/40 mg per 5 mL
Dosage form
Oral suspension
Route
Oral
Packs
473 mL
Marketing authorisation holder
PAI Pharma
Manufacturers
PAI PharmaA-S Medication SolutionsPreferred Pharmaceuticals
Origin register
US FDA, United States
Storage
Store at 20°-25°C (68°-77°F). Protect from light.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
J01EE01 Sulfamethoxazole and Trimethoprim
HS code (indicative)
3004.20Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
3 July 1983
Identifiers
RxCUI 208406, 313134DailyMed set ID c62086ea-ba15-40f5-8431-4639c60c9825, 80f7f00b-add4-4d6b-9e9c-bea29768c239, cd4932ce-0856-4e99-8baf-70afce1d7ffdNDC 0121-0854, 50090-7836, 68788-7345Application NDA018615

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
473 mL in 1 bottle0121-0854-16PAI Pharma3 July 1983
473 mL in 1 bottle50090-7836-0A-S Medication Solutions29 December 2025
473 mL in 1 bottle68788-7345-4Preferred Pharmaceuticals1 June 2020

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 30 July 1973Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Sulfamethoxazole and Trimethoprim 200 mg/40 mg per 5 mL oral suspension.

Compare 1

Other strengths and forms of Sulfamethoxazole and Trimethoprim

Clinical summary

Sulfamethoxazole and Trimethoprim is a fixed-dose combination of a dihydrofolate reductase inhibitor antibacterial and a sulfonamide antimicrobial indicated for prophylactic or prolonged administration in otitis media at any age. MedsAcross supplies Sulfamethoxazole and Trimethoprim for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Sulfamethoxazole and Trimethoprim

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Sulfatrim 200 mg/40 mg per 5 mL oral suspension for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.